FINWIRES · TerminalLIVE
FINWIRES

Fennec Pharmaceuticals up 12.6% in U.S. Pre-Market on Q1 Earnings as Pedmark Sales Jump 73%

By

Fennec Pharmaceuticals (FRX.TO), up 12.6% in U.S. pre-market trading, Thursday reported a swing to a first-quarter profit as sales of Pedmark surged.

The company, which developed Pedmark or sodium thiosulfate injection, to reduce the risk of cisplatin-induced hearing loss in pediatric patients, reported a profit of US$0.2 million, or US$0.01 per share, compared with a loss of US$1.2 million, or US$0.04 per share, in the prior year period. Analysts polled by FactSet had forecast a loss of US$0.04 per share.

Fennec booked net product sales of US$15.1 million, compared with US$8.8 million last year. Analysts had expected US$13.9 million. The increase is due to growth across Pedmark accounts, including new accounts in the adolescent and young adult (AYA) population. Demand in the first quarter was driven by prescribing in three core tumor types: testicular, cervical and head and neck cancers, and these remain foundational to Fennec's commercial opportunity, Fennec said.

"We are encouraged by our continued quarter-over-quarter growth and strong start to the year. 2026 is a defining period for Fennec, with growing clinical interest in independently evaluating PEDMARK(r) (sodium thiosulfate injection) across new patient populations and tumor types that reinforces our confidence in its broader potential," said Jeff Hackman, chief executive officer.

Fennec Pharmaceuticals was last seen up US$0.85, to US$7.62 in New York trading. It closed down $0.30, to $9.28, on the Toronto Stock Exchange.

Related Articles

Mining & Metals

Calian Group Up 11% On Improved Q2 Net Profit, Revenue

Calian Group (CGY.TO) was at last look up 11% in early Thursday trade after reporting higher net profit and revenue in the second quarter as the company begins to "capture the benefits of strengthening demand across the defence sector".For Q1, second quarter net profit was C$6.7 million, or $0.58 per diluted share, compared to $0.3 million, or $0.02 per diluted share in the corresponding year-ago quarter. The increase is primarily related to higher adjusted EBITDA and lower mergers and acquisition costs, partially offset by higher restructuring expenses and taxes, said the company.Second quarter adjusted net profit was $15.1 million, or $1.30 per diluted share, up from $9.1 million, or $0.77 per diluted share, in the year-ago quarter.Second quarter revenue was a record $228.7 million, compared to $193.7 million in the year-ago quarter. The consensus estimates compiled by FactSet for Sales was $215.7 million.Acquisitive growth was 6% and was generated by the acquisitions of Advanced Medical Solutions completed in May 2025 and Infield Scientific closed in October 2025. Organic growth was 12% and was generated by both the Defence & Space and Essential Industries segments.On May 13, 2026, the company declared a quarterly dividend of $0.28 per share, unchanged from the prior quarter. The dividend is payable June 10, 2026, to shareholders of record as of May 27, 2026."Our second quarter results mark an important inflection point for Calian as we begin to capture the benefits of strengthening demand across the defence sector," said Patrick Houston, Calian Chief Executive Officer.He added: "Revenue grew 18%, including 12% organic growth, which was achieved through record-setting deliveries and a strong pace of contract signings. This solid top-line performance translated into an 60% increase in adjusted EBITDA, which significantly outpaced revenue growth and reflects the compounded impact of higher volumes and improved operational leverage."These results reflect early but tangible momentum in government defence spending and validate the strategic choices we have made to sharpen our operating model. With a $1.5 billion backlog, a robust acquisition pipeline, and a solid balance sheet, we are well-positioned to capture market share, deliver strong full year performance, and create lasting value for shareholders."Price: $77.23, Change: $+9.23, Percent Change: +13.57%

$CGY.TO
Mining & Metals

TSX Now Up Nearer 50 Pts, Was Up About 115 Pts; Comes After It Lost Near 250 Pts Wednesday, Its First Loss in 4 Sessions

$^GSPTSE$.GSPTSE
Mining & Metals

Yellow Pages' Q1 Net Income Slides YoY

Canadian digital media and marketing company Yellow Pages (Y.TO) saw a drop in net income year over year in the first quarter on lower Adjusted EBITDA amid global economic challenges that impacted its revenue initiatives, the company said Thursday.The company posted a net income of C$4.1 million, or $0.30 per diluted share, in the three months ended March 31, down from near $5.0 million, or $0.35 per share diluted, in the previous year.Revenue fell to $46.83 million in the first quarter from $50.8 million a year ago, while adjusted EBITDA dropped to just over $9.0 million from near $11.9 million.It said the decrease in revenues is mainly due to the decline of its higher margin digital media and print products and to a lesser extent to its lower margin digital services products, thereby creating pressure on gross profit margins. The total revenues decline of 7.8% for the three-month period ended March 31, 2026 compares to 7.6% reported for the same period last year. The higher decline rate is driven by the decline in print revenue while the decline rate for digital has improved.The company declared a dividend of $0.25 per common share, to be paid June 15 to shareholders of record as of May 25. The dividend was unchanged from the previous quarter.

$Y.TO